Icatibant公司
遗传性血管水肿
医学
缓激肽
激肽释放酶
C1抑制剂
血管性水肿
皮肤病科
药品
药理学
受体拮抗剂
皮下注射
敌手
标识
DOI:10.58347/tml.2026.1748c
摘要
Sebetralstat (Ekterly – Kalvista), an oral plasma kallikrein inhibitor, has been approved by the FDA for treatment of acute hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first oral drug to be approved in the US for this indication. The intravenous C1 esterase inhibitors (C1INHs) Berinert and Ruconest, the subcutaneous plasma kallikrein inhibitor ecallantide (Kalbitor), and the subcutaneous bradykinin B2 receptor antagonist icatibant (Firazyr) have been available for years for on-demand treatment of HAE attacks; all of these drugs except ecallantide can be self-administered, but treatment delays are common.
科研通智能强力驱动
Strongly Powered by AbleSci AI